发明公开
EP3021944A1 IGF-1R SIGNALING PATHWAY INHIBITORS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
审中-公开
IGF-1R SIGNALWEGINHIBITOREN用于治疗神经退行性疾病
- 专利标题： IGF-1R SIGNALING PATHWAY INHIBITORS USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES
- 专利标题（中）： IGF-1R SIGNALWEGINHIBITOREN用于治疗神经退行性疾病
-
申请号： EP14825966.6申请日： 2014-07-13
-
公开(公告)号： EP3021944A1公开(公告)日： 2016-05-25
- 发明人: REUVENI, Hadas , COHEN, Ehud , LEVITSKI, Alexander , BEN-SASSON, Shmuel
- 申请人： Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
- 申请人地址： Hi Tech Park Edmond J. Safra Campus Givat Ram P.O. Box 39135 91390 Jerusalem IL
- 专利权人： Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
- 当前专利权人： Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.
- 当前专利权人地址： Hi Tech Park Edmond J. Safra Campus Givat Ram P.O. Box 39135 91390 Jerusalem IL
- 代理机构： Becker Kurig Straus
- 优先权： US201361846014P 20130714
- 国际公布： WO2015008206 20150122
- 主分类号： A61P25/00
- IPC分类号： A61P25/00 ; A61K31/5415 ; C07C327/44 ; A61K31/165 ; C07D277/36
摘要：
The present invention provides compounds acting as Insulin/IGF signaling modulators useful in the treatment of neurodegenerative diseases and disorders. The invention provides pharmaceutical compositions including such compounds, and methods of using these compounds and compositions for the treatment of neurodegenerative diseases, in particular neurodegenerative diseases caused by proteotoxicity such as Alzheimer's disease.
信息查询
